Adie Rae (Wilson-Poe), Ph.D.
Dr. Wilson-Poe received her BS in Psychology and her PhD in Neuroscience from Washington State University, where she focused on the pain-relieving properties of opioids and cannabinoids. Adie followed up on this training by taking a post-doctoral position at Sydney University in Australia, where she was awarded a National Research Service Award from the National Institute on Drug Abuse (NIDA) to study the synaptic physiology of cannabinoids and opioids.
Dr. Wilson-Poe continued her post-doctoral training at Columbia University, where she broadened her expertise to include the dynamic interaction between drug abuse and chronic pain. As a junior faculty member at Washington University in St. Louis, Adie was awarded a prestigious Pathway to Independence Award from NIDA, which integrates all previous facets of her work.
Adie joined Legacy Research Institute in June of 2019, and she currently utilizes translational and clinical research approaches to further characterize the analgesic and harm-reducing properties of cannabis, in the context of opioid use.
The Nose Knows: Aroma, but Not THC Mediates the Subjective Effects of Smoked and Vaporized Cannabis Flower
Perceived Efficacy, Reduced Prescription Drug Use, and Minimal Side Effects of Cannabis in Patients with Chronic Orthopedic Pain
Pain-Induced Negative Affect Is Mediated Via Recruitment Of The Nucleus Accumbens Kappa Opioid System
Emerging Evidence for Cannabis' Role in Opioid Use Disorder
The central hypothesis of Dr. Wilson-Poe’s work is that cannabis and cannabinoids can be leveraged for their pain-relieving and harm-reducing properties, to reduce societal dependence upon opioids. Dr. Wilson-Poe’s early work was focused on the mechanisms of cannabinoid/opioid analgesia, with her first grant from WSU’s Alcohol and Drug Abuse Research Program in 2004. This funding opportunity fueled all of her subsequent studies (ranging from synaptic physiology to in-vivo opto- and chemo-genetic modulation of behavior), which have been consistently funded by NIDA. Dr. Wilson-Poe’s long-term research goal is to bridge the gap between preclinical cannabinoid pharmacology and clinical cannabis medicine by using translational approaches. In support of this goal, Adie has several ongoing research tracks:
Combined Buprenorphine and Cannabis for Pain
Measuring Cannabis Use in Medical Patients
Measuring the Safety, Effectiveness, and Equity of Supervised Psilocybin Services
The Impact of Adult-Use Cannabis Legislation on Patient Wellbeing
Safety of Vaporizer Cartridge Diluents